Chicago Equity Partners’s Pacira BioSciences PCRX Stock Holding History

Chicago Equity Partners’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-102,125	Closed	-$4.44M	–	943
2019 Q2	$4.44M	Buy	102,125 +32,585	+47%	+$1.38M	0.2%	129
2019 Q1	$2.65M	Sell	69,540 -20,720	-23%	-$809K	0.1%	278
2018 Q4	$3.88M	Sell	90,260 -3,380	-4%	-$158K	0.16%	179
2018 Q3	$4.6M	Buy	+93,640	New	+$4.05M	0.14%	198
2017 Q3	–	Sell	-12,600	Closed	-$601K	–	798
2017 Q2	$601K	Buy	+12,600	New	+$585K	0.02%	600
2014 Q4	–	Sell	-2,150	Closed	-$208K	–	444
2014 Q3	$208K	Sell	2,150 -150	-7%	-$14.6K	0.01%	420
2014 Q2	$211K	Buy	+2,300	New	+$175K	0.01%	411
2013 Q4	–	Sell	-4,450	Closed	-$213K	–	460
2013 Q3	$213K	Buy	+4,450	New	+$162K	0.01%	410

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Chicago Equity Partners's PCRX Position: Q3 2019 in Review

Chicago Equity Partners sold out of Pacira BioSciences (PCRX) in Q3 2019, closing a stake of 102,125 shares — an estimated $4.44M sold.

Chicago Equity Partners first reported a position in PCRX in Q3 2013 and held it in 8 quarters. The position peaked at $4.6M in Q3 2018. 211 funds tracked by Wall St. Rank hold PCRX as of Q3 2019.

Chicago Equity Partners reported no remaining Pacira BioSciences position as of Q3 2019 after selling out during the quarter.
Chicago Equity Partners sold 102,125 Pacira BioSciences shares in Q3 2019, an estimated $4.44M.
Chicago Equity Partners first reported a position in Pacira BioSciences in Q3 2013 and held it in 8 quarters.
Chicago Equity Partners's Pacira BioSciences position peaked at $4.6M in Q3 2018.
211 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2019.

Based on Chicago Equity Partners's 13F filing for Q3 2019, filed 30 Oct 2019.